Damian Clarke-Bruce
Amministratore Delegato presso HaemaLogiX Pty Ltd.
Patrimonio netto: 5 556 $ in data 30/04/2024
Relazioni attive
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
John Cullity | M | - |
HaemaLogiX Pty Ltd.
HaemaLogiX Pty Ltd. BiotechnologyHealth Technology HaemaLogiX Pty Ltd. is a biotech company located in Sydney, Australia. The Australian company has a wide range and depth of experience in antibody research, nonclinical & clinical development, manufacturing, and commercialization. The scientific advisory board members are internationally recognized experts in monoclonal antibody therapies and hematology. The company's current research and clinical trial partners are leaders in multiple myeloma and AL amyloidosis therapy. Founded in 2014, the company is researching immune-based treatments such as monoclonal antibodies, CAR T cell therapies, and bispecific antibodies to target unique antigens on malignant cells and improve the quality of life of patients suffering from blood cancers like multiple myeloma and other life-threatening diseases like AL amyloidosis. Bryce D. Carmine has been the CEO of the company since 2015. | 9 anni |
Bryce D. Carmine | M | 72 |
HaemaLogiX Pty Ltd.
HaemaLogiX Pty Ltd. BiotechnologyHealth Technology HaemaLogiX Pty Ltd. is a biotech company located in Sydney, Australia. The Australian company has a wide range and depth of experience in antibody research, nonclinical & clinical development, manufacturing, and commercialization. The scientific advisory board members are internationally recognized experts in monoclonal antibody therapies and hematology. The company's current research and clinical trial partners are leaders in multiple myeloma and AL amyloidosis therapy. Founded in 2014, the company is researching immune-based treatments such as monoclonal antibodies, CAR T cell therapies, and bispecific antibodies to target unique antigens on malignant cells and improve the quality of life of patients suffering from blood cancers like multiple myeloma and other life-threatening diseases like AL amyloidosis. Bryce D. Carmine has been the CEO of the company since 2015. | 9 anni |
Leonard Kruimer | M | 66 | 3 anni | |
Peter Smith | M | 61 | 1 anni | |
Ruud van Outersterp | M | 60 | 4 anni | |
Rosanne Dunn | M | - |
HaemaLogiX Pty Ltd.
HaemaLogiX Pty Ltd. BiotechnologyHealth Technology HaemaLogiX Pty Ltd. is a biotech company located in Sydney, Australia. The Australian company has a wide range and depth of experience in antibody research, nonclinical & clinical development, manufacturing, and commercialization. The scientific advisory board members are internationally recognized experts in monoclonal antibody therapies and hematology. The company's current research and clinical trial partners are leaders in multiple myeloma and AL amyloidosis therapy. Founded in 2014, the company is researching immune-based treatments such as monoclonal antibodies, CAR T cell therapies, and bispecific antibodies to target unique antigens on malignant cells and improve the quality of life of patients suffering from blood cancers like multiple myeloma and other life-threatening diseases like AL amyloidosis. Bryce D. Carmine has been the CEO of the company since 2015. | - |
Mark Pykett | M | 60 | 4 anni | |
Geoffrey Nichol | M | 69 |
HaemaLogiX Pty Ltd.
HaemaLogiX Pty Ltd. BiotechnologyHealth Technology HaemaLogiX Pty Ltd. is a biotech company located in Sydney, Australia. The Australian company has a wide range and depth of experience in antibody research, nonclinical & clinical development, manufacturing, and commercialization. The scientific advisory board members are internationally recognized experts in monoclonal antibody therapies and hematology. The company's current research and clinical trial partners are leaders in multiple myeloma and AL amyloidosis therapy. Founded in 2014, the company is researching immune-based treatments such as monoclonal antibodies, CAR T cell therapies, and bispecific antibodies to target unique antigens on malignant cells and improve the quality of life of patients suffering from blood cancers like multiple myeloma and other life-threatening diseases like AL amyloidosis. Bryce D. Carmine has been the CEO of the company since 2015. | 2 anni |
Alan Liddle | M | - |
HaemaLogiX Pty Ltd.
HaemaLogiX Pty Ltd. BiotechnologyHealth Technology HaemaLogiX Pty Ltd. is a biotech company located in Sydney, Australia. The Australian company has a wide range and depth of experience in antibody research, nonclinical & clinical development, manufacturing, and commercialization. The scientific advisory board members are internationally recognized experts in monoclonal antibody therapies and hematology. The company's current research and clinical trial partners are leaders in multiple myeloma and AL amyloidosis therapy. Founded in 2014, the company is researching immune-based treatments such as monoclonal antibodies, CAR T cell therapies, and bispecific antibodies to target unique antigens on malignant cells and improve the quality of life of patients suffering from blood cancers like multiple myeloma and other life-threatening diseases like AL amyloidosis. Bryce D. Carmine has been the CEO of the company since 2015. | 11 anni |
Jeroen Wakkerman | M | 55 | 4 anni | |
Steven Baert | M | 50 | 3 anni | |
Barbara Yanni | F | 69 | 4 anni | |
Jabine T. M. van der Meijs | M | 58 | 3 anni | |
Stephen Toor | M | 52 | 4 anni | |
Tim Hammond | M | - | 1 anni | |
Michelle Rashford | M | - | 1 anni |
Grafico relazionale
Relazione in diverse aziende
Relazioni precedenti
Nome | Sesso | Età | Società collegate | Collaborazione |
---|---|---|---|---|
Daniel Tillett | M | - | 4 anni | |
John Barrie Ward | M | 86 | 14 anni | |
Juergen H. L. Ernst | M | 85 | 11 anni | |
Aad de Winter | M | 71 | 12 anni | |
Daniel Sharp | M | - | 1 anni | |
Anne-Marie de Groot | F | 43 | 7 anni | |
Robin Wright | M | 59 | 5 anni | |
Robert Friesen | M | 60 | - | |
Ajay Duggal | M | - | 1 anni |
Statistiche
Paese | Relazioni | % del totale |
---|---|---|
Paesi Bassi | 14 | 56.00% |
Australia | 11 | 44.00% |
Età delle relazioni
Attive
Scorse
Uomo
Donna
Amministratori
Dirigenti
Provenienza delle relazioni
- Borsa valori
- Insiders
- Damian Clarke-Bruce
- Contatti personali